

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	October 21, 2003
				First Named Inventor	Arthur L. Holden
				Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	FGTI-P02-004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
<i>1/2</i>	AA**	US-5924074	07/1999	Evans	
<i>1/2</i>	AB**	US-5897989	04/1999	James E. Beecham	
<i>1/2</i>	AC**	US-4683195	07/1987	Mullis, et al.	
<i>1/2</i>	AD**	US-5050613	09/1991	Newman, et al.	
<i>1/2</i>	AE**	US-5523208	06/1996	Kohler, et al.	
<i>1/2</i>	AF**	US-5834181	11/1998	Anthony P. Shuber	
<i>1/2</i>	AG**	US-5876926	03/1999	James E. Beechman	
<i>1/2</i>	AH**	US-5920871	07/1999	Macri, et al.	
<i>1/2</i>	AI**	US-5941947	08/1999	Brown, et al.	
<i>1/2</i>	AJ**	US-5993387	11/1999	Moore, et al.	
<i>1/2</i>	AK**	US-6253203	06/2001	O'Flaherty, et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
<i>1/2</i>	BA**	WO-97/31327	08-28-1997		
<i>1/2</i>	BB**	EA-0913758	05-06-1999		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
<i>1/2</i>	CA**	Pulst, S.M., 1999 Neurol., Vol. 56, No. 6, "Genetic Linkage Analysis", pp. 667-672			
<i>1/2</i>	CB**	Ballantyne, et al., 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Molecular Markers for Atherosclerosis", pp. 353-356			
<i>1/2</i>	CC**	Marian, A.J. 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Genetic Markers: Genes Involved in Human Hypertension", pp. 341-345			
<i>1/2</i>	CD**	Marian, A.J. 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Genetic Markers: Genes Involved in Atherosclerosis", pp. 333-339			
<i>1/2</i>	CE**	Hallman, D.M., et al., 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Molecular and Genetic Approaches to the Study of Cardiovascular Disease###", pp. 325-331			
<i>1/2</i>	CF**	Ballantyne, et al., 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Genetic and Molecular Markers for Vascular Disease", pp. 321-323			
<i>1/2</i>	CG**	Zehbe, et al., 1999 Lancet, Vol. 354 (9174), "Condon 72 Polymorphism of p53 and Its Association with Cervical Cancer", pp. 218-219			
<i>1/2</i>	CH**	Hakansson, et al., 1997 Am. J. Hum. Genet., Vol. 60, No. 5, "Moderate Frequency of BRCA1 and BRCA2 Germ-Line Mutations in Scandinavian Familial Breast Cancer", pp. 1068-1078			
<i>1/2</i>	CI**	Vaidya, et al., 1999 Lancet, Vol. 354 (9180), "Cytotoxic T Lymphocyte Antigen-4 (CTLA04) Gene			


Examiner Signature	Date Considered	3/3/05
--------------------	-----------------	--------

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	October 21, 2003
				First Named Inventor	Arthur L. Holden
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	FGTI-P02-004

		Polymorphism Confers Susceptibility to Thyroid Associated Orbitopathy", pp. 743-744	
	CJ**	Liao, et al., 1999 Angiology, Vol. 50, No. 8, "A Missense Mutation of the Nitric Oxide Synthase (eNOS) Gene (Clu298Asp) in Five Patients with Coronary Arter Disease", pp. 671-676	
	CK**	Rust, et al., 1999 Nat. Genet. Vol. 22, No. 4, "Tangier Disease id Caused by Mutations in the Gene Encoding ATP-Bidning Cassette Transporter 1", pp. 352-355	
	CL**	Brooks-Wilson, 1999 Nat. Genet., Vol. 22, No. 4, "Mutations in ABC1 Tangier Disease and Familial High-Density Lipoprotein Deficiency", pp. 336-345	
	CM**	Ligers, et al., 1999 Neuroimmunol., Vol. 97-102, "The CTLA-4 Gene is Associated with Multiple Sclerosis", pp. 182-190	
	CN**	Shinar, et al., 1998 J. Mol. Neurosci., Vol. 11, No. 3, "Analysis of Allelic Association Between D6S461 Marker and Multiple Sclerosis in Ashkenazi and Iraqi Jewish Patients", pp. 265-269	
	CO**	Schutte, et al., 1999 Am. J. Med. Genet., Vol. 84, No. 2, "Microdeletions at Chromosome Bands 1q32-q41 As A Cause of Van der Woude Syndrome", pp. 145-150	
	CP**	Aita, et al., 1999 Am. J. Hum. Genet., Vol. 64, No. 1, "A Comprehensive Linkage Analysis of Chromosome 21q22 Supports Prior Evidence for A Putative Biopolar Affective Disorder Locus", pp. 210-217	
	CQ**	Campbell, et al., 1999 Mol. Psychiatry, Vol. 4, No. 1, "Association Between A Marker in the UCP-2/UCP-3 Gene Cluster and Genetic Susceptibility to Anorexia Nervosa", pp. 68-70	
	CR**	Scacchi, et al., 1999 Neurosci. Lett., Vol. 259, No. 1, "Plasma Levels of Apolipoprotein E and Genetic Markers in Elderly Patients with Alzheimer's Disease", pp. 33-36	
	CS**	Kruger, et al., 1999 Ann. Neurol., Vol. 45, No. 5, "Increased Susceptibility to Sporadic Parkinson's Disease By A Certain Combined a-Synuclein/Apolipoprotein E Genotype", pp. 611-617	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/31/05
--------------------	---	-----------------	---------